

19 November 2013
ASX Release

Actinogen Limited (ASX Code: ACW)

Appointment of Executive Director

Actinogen Limited is pleased to announce the appointment of Dr Brendan de Kauwe to the role of Executive Director, effective 19 November 2013.

The Board is extremely pleased to have secured Dr de Kauwe to take the lead role in directing the Company's projects to the next level of generation and development.

Dr de Kauwe said "I am very excited to be entrusted with the lead role in the Company moving forward. We are currently in the process of relocating our laboratory to new premises, and have secured the services of our core research team, headed by one of our founders Dr David Keast".

"Our team is currently working on the reporting and evaluation of the previous trials conducted earlier this year. We are also preparing the relevant data and processes to further explore the expressed third party interest over the past months in a number of our focalactinomycetes projects, and we look forward in announcing further information to the market as these interests unfold. I am confident in a bright future for the Company and that we can deliver real shareholder value with our newly invigorated team."

Dr de Kauwe's appointment will be reviewed after an initial period of six months and his remuneration will be \$5,000 per month.

About Dr Brendan de Kauwe BDS (UWA), Grad Dip App Fin

Dr de Kauwe studied a Bachelor of Science and a Bachelor of Dental Surgery at the University of Western Australia. He also holds a Post Graduate Diploma in Applied Finance, majoring in Corporate Finance, is currently completing his Masters in Applied Finance and is an ASIC compliant (RG146) Securities Adviser.

Dr de Kauwe's extensive science and bio-medical background with more than 10 years' experience in the health sector; coupled with his finance backing, gives him an integral understanding in the evaluation of projects over a diverse range of sectors.

Dr de Kauwe is currently a Director of ASX listed Virax Holdings Limited (ASX Code: VHL).

About Actinogen Limited Actinogen Limited (ASX: ACW)

Actinogen is dedicated to the discovery and isolation of a group of environmental bacteria known as the Actinomycetes. Actinomycetes have been shown to be able to use a wide range of unusual nutritional resources and often produce bioactive molecules as a by-product that have been proven to be useful to man; including well known commercial examples such as bacterial antibiotics, anti fungal agents, anticancer agents and a variety of other chemicals that are used in the control of physiological and physical processes.

In addition, there are examples of Actinomycetes that can degrade industrial wastes such as oils, tar, domestic and industrial waste, and the rehabilitation of oil spills. Actinogen has proven high-level expertise in the discovery and isolation of Actinomycetes from WA soils and in the detection of bioactive molecules they produce. During 2011, Actinogen began a bio-ethanol research program, which has had very encouraging results and to date is a focal project for the company. The Company's strategy is to collaborate with groups nationally and internationally who are active in the development of technology that is synergistic with or that could utilise the Company's current Actinomycetes research projects and exclusive intellectual property.